A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Rivipansel (pf 06460031) Following Subcutaneous Administration With Rhuph20 (pf 06744547) In Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Rivipansel (pf 06460031) Following Subcutaneous Administration With Rhuph20 (pf 06744547) In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2016

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Apr 2016 Status changed from recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 23 Dec 2015 Crossover assignment has been removed from the trial design as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top